DYAI - DYADIC INTERNATIONAL INC

1.2
-0.020   -1.667%

Share volume: 15,671
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$1.22
-0.02
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 25%
Dept financing 13%
Liquidity 75%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.00%
1 Month
-13.67%
3 Months
-27.27%
6 Months
6.19%
1 Year
-37.17%
2 Year
-32.58%
Key data
Stock price
$1.20
P/E Ratio 
0.00
DAY RANGE
$1.20 - $1.32
EPS 
-$0.20
52 WEEK RANGE
$0.93 - $2.67
52 WEEK CHANGE
-$33.70
MARKET CAP 
51.781 M
YIELD 
N/A
SHARES OUTSTANDING 
29.478 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$29,213
AVERAGE 30 VOLUME 
$54,161
Company detail
CEO: Mark A. Emalfarb
Region: US
Website: dyadic.com
Employees: 7
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.

Recent news
loading